Pharmacological therapy for cystic fibrosis: From bench to bedside

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Becq, Frédéric ^a   Mall, Marcus A ^b   Sheppard, David N ^c   Conese, Massimo ^d,e   Zegarra Moran, Olga ^f  

^a UNIVERSITÉ DE POITIERS   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Institute for the Experimental Treatment of Cystic Fibrosis   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f G GASLINI INSTITUTE   (Italy)

Author keywords

Airway surface fluid; CFTR; CFTR correctors; CFTR potentiators; ENaC; F508del

Indexed keywords

3 (2 BENZYLOXYPHENYL)ISOXAZOLE; 4 CLOHEXYLOXY 2 [1 [4 (4 METHOXY BENZENSULFUNOYL) PIPERAZIN 1 YL] ETHYL] QUINAZOLINE; 4 PHENYLBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; APIGENIN; APIGENIN DERIVATIVE; ARYLBUTYRIC ACID DERIVATIVE; BENZOFLAVONE DERIVATIVE; BORTEZOMIB; CAPSAICIN; CASTANOSPERMINE; CURCUMIN; CYCLOPIAZONIC ACID; DENUFOSOL; DIHYDROPYRIDINE; EPOXOMICIN; GENISTEIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; ISOXAZOLE; IVACAFTOR; MIGLUSTAT; PHLOXINE; QUINAZOLINE; SILDENAFIL; SULFONAMIDE; THAPSIGARGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VRT 325; ZAPRINAST;

AMINO ACID SEQUENCE; APICAL MEMBRANE; ARTICLE; BIOCHEMISTRY; BIOSYNTHESIS; CELL MIGRATION; CELL SURFACE; CHANNEL GATING; CHLORIDE TRANSPORT; CODON; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ELECTROPHYSIOLOGY; EPITHELIUM; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE MUTATION; HIGH THROUGHPUT SCREENING; IMMUNOCYTOCHEMISTRY; INTRACELLULAR TRANSPORT; ION TRANSPORT; LUNG DISEASE; LUNG FUNCTION; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RNA INTERFERENCE; SINGLE DRUG DOSE;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; DRUG INDUSTRY; EPITHELIAL SODIUM CHANNEL; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS;

EID: 79958104493     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60018-0     Document Type: Article

References (150)

1. Davis PB Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006, 173:475-482.
2. Dodge JA, Lewis PA, Stanton M, Wilsher J Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007, 29:522-526.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
4. Sheppard DN, Welsh MJ Structure and function of the CFTR chloride channel. Physiol Rev 1999, 79(1 Suppl):S23-S45.
5. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999, 79(1 Suppl):S 145-S 166.
6. Welsh MJ, Ramsey BW, Accurso F, Cutting GR Cystic Fibrosis. The Metabolic and Molecular Basis of Inherited Disease 2001, 5121-5188. McGraw-Hill Inc., New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
7. Rowe SM, Miller S, Sorscher EJ Cystic fibrosis. N Engl J Med 2005, 352:1992-2001.
8. Conese M, Ascenzioni F, Boyd AC, et al. Gene and cell therapy for cystic fibrosis: From bench to bedside. J Cyst Fibros 2011, 10(Suppl 2):114-128.
9. Welsh MJ, Smith AE Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73:1251-1254.
10. Zielenski J, Tsui LC Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995, 29:777-807.
11. Amaral MD Processing of CFTR: traversing the cellular maze - how much CFTR needs to go through to avoid cystic fibrosis?. Pediatr Pulmonol 2005, 39:479-491.
12. - channel by ATP-driven nucleotide-binding domain dimerisation. J Physiol 2009, 587:2151-2161.
13. - channels with altered pore properties. Nature 1993, 362:160-164.
14. Tabcharani JA, Rommens JM, Hou YX, et al. Multi-ion pore behaviour in the CFTR chloride channel. Nature 1993, 366:79-82.
15. Sheppard DN, Ostedgaard LS, Winter MC, Welsh MJ Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. EMBO J 1995, 14:876-883.
16. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990, 63:827-834.
17. Denning GM, Ostedgaard LS, Cheng SH, Smith AE, Welsh MJ Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J Clin Invest 1992, 89:339-349.
18. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 1991, 354:526-528.
19. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992, 358:761-764.
20. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
21. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
22. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the a-glucosidase inhibitor miglustat. FEBS Lett 2006, 580:2081-2086.
23. Noël S, Wilke M, Bot AG, De Jonge HR, Becq F Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008, 325:1016-1023.
24. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005, 115:2564-2571.
25. Van Goor F, Straley KS, Cao D, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1117-L1130.
26. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809. J Cyst Fibros 2010, 9(Suppl 1):S14.
27. Clancy JP, Spencer-Green G, for the VX-809-101 Study Group Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. J Cyst Fibros 2010, 9(Suppl 1):S20.
28. Pedemonte N, Tomati V, Sondo E, Galietta LJ Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 2010, 298:C866-C874.
29. Wang Y, Bartlett MC, Loo TW, Clarke DM Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 2006, 70:297-302.
30. Becq F, Jensen TJ, Chang XB, et al. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci U S A 1994, 91:9160-9164.
31. Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang TC Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating: evidence for two binding sites with opposite effects. J Gen Physiol 1998, 111:477-490.
32. - channel. Trends Pharmacol Sci 1999, 20:448-453.
33. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009, 106:18825-18830.
34. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
35. - channels. J Gen Physiol 2003, 121:17-36.
36. Vergani P, Lockless SW, Nairn AC, Gadsby DC CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005, 433:876-880.
37. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004, 23:282-293.
38. Aleksandrov L, Aleksandrov AA, Chang XB, Riordan JR The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover. J Biol Chem 2002, 277:15419-15425.
39. Ai T, Bompadre SG, Wang X, Hu S, Li M, Hwang TC Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 2004, 65:1415-1426.
40. Moran O, Galietta LJ, Zegarra-Moran O Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005, 62:446-460.
41. Zegarra-Moran O, Monteverde M, Galietta LJ, Moran O Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators: interaction between activation and inhibition. J Biol Chem 2007, 282:9098-9104.
42. + channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Exp Physiol 2009, 94:171-174.
43. - channels. Physiology (Bethesda) 2010, 25:357-363.
44. Schultz BD, Singh AK, Devor DC, Bridges RJ Pharmacology of CFTR chloride channel activity. Physiol Rev 1999, 79(1 Suppl):S109-S144.
45. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269:847-850.
46. + conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 1998, 102:15-21.
47. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
48. Stutts MJ, Rossier BC, Boucher RC Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 1997, 272:14037-14040.
49. Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzy JT, Boucher RC Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983, 221:1067-1070.
50. - secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266:C1478-C1483.
51. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493.
52. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
53. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990, 322:1189-1194.
54. Köhler D, App E, Schmitz-Schumann M, Würtemberger G, Matthys H Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibröses. Eur J Respir Dis Suppl 1986, 146:319-326.
55. App EM, King M, Helfesrieder R, Köhler D, Matthys H Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990, 141:605-612.
56. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993, 6:1243-1248.
57. Bowler IM, Kelman B, Worthington D, et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995, 73:427-430.
58. Pons G, Marchand MC, d'Athis P, et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients: the Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 2000, 30:25-31.
59. Mall MA Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 2008, 21:13-24.
60. Hirsh AJ Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 2002, 54:1445-1462.
61. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008, 325:77-88.
62. Coote KJ, Atherton H, Young A, et al. The guinea-pig trachéal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways. Br J Pharmacol 2008, 155:1025-1033.
63. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006, 354:241-250.
64. + channel and airway surface liquid volume by serine proteases. Pflugers Arch 2010, 460:1-17.
65. + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol Lung Cell Mol Physiol 2001, 281:L16-L23.
66. Donaldson SH, Hirsh A, Li DC, et al. Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem 2002, 277:8338-8345.
67. Coote K, Atherton-Watson HC, Sugar R, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009, 329:764-774.
68. Dykxhoorn DM, Novina CD, Sharp PA Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003, 4:457-467.
69. Caci E, Melani R, Pedemonte N, et al. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am J Respir Cell Mol Biol 2009, 40:211-216.
70. Li T, Folkesson HG RNA interference for a-ENaC inhibits rat lung fluid absorption in vivo. Am J Physiol Lung Cell Mol Physiol 2006, 290:L649-L660.
71. Li T, Koshy S, Folkesson HG RNA interference for CFTR attenuates lung fluid absorption at birth in rats. Respir Res 2008, 9:55.
72. Griesenbach U, Kitson C, Escudero Garcia S, et al. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res 2006, 7:26.
73. Anderson MP, Sheppard DN, Berger HA, Welsh MJ Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. Am J Physiol 1992, 263:L1-14.
74. Knowles MR, Clarke LL, Boucher RC Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991, 325:533-538.
75. Mason SJ, Paradiso AM, Boucher RC Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 1991, 103:1649-1656.
76. + absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am J Respir Cell Mol Biol 2000, 23:755-761.
77. Tarran R, Grubb BR, Parsons D, et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001, 8:149-158.
78. 2 agonists that led to Phase 3. Pulm Pharmacol Ther 2008, 21:600-607.
79. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008, 322:5904.
80. Schroeder BC, Cheng T, Jan YN, Jan LY Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008, 134:1019-1029.
81. Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008, 455:1210-1215.
82. Namkung W, Phuan PW, Verkman AS TMEM16A inhibitors reveal TMEM16A as a minor component of CaCC conductance in airway and intestinal epithelial cells. J Biol Chem 2011, 286:2365-2374.
83. Becq F Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Drugs 2010, 70:241-259.
84. - channel function. Mol Med Today 1996, 2:290-297.
85. Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis: Phenotypic analysis and research applications. J Cyst Fibros 2011, 10(Suppl 2):152-171.
86. - channel with the gating behavior of murine CFTR. Proc Nati Acad Sei U S A 2007, 104:16365-16370.
87. de Jonge H, Wilke M, Bot A, Sheppard DN Responsiveness of mouse versus human CFTR-ΔF508 to small molecule correctors and potentiators. Pediatr Pulmonol Suppl 2009, 32:291-292.
88. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321:1837-1841.
89. Mehta G, Macek M, Mehta A, European Registry Working Group Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010, 9(Suppl 2):S5-21.
90. De Boeck K, Bulteel V, Tiddens H, on behalf of all ECFS-CTN network partners, et al. Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J Cyst Fibros 2011, 10(Suppl 2):67-74.
91. Schlangen M, Reimann ALG Developing new products in cystic fibrosis: Needs and obstacles for activities of small and middle-sized companies. J Cyst Fibros 2011, 10(Suppl 2):103-109.
92. Egan ME, Glöckner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002, 8:485-492.
93. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304:600-602.
94. Lipecka J, Norez C, Bensalem N, et al. Rescue of ΔF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J Pharmacol Exp Ther 2006, 317:500-505.
95. 2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 2006, 7:562-573.
96. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm 2010, 7:86-93.
97. Wilke M, Bot AG, Jorna H, Marino CR, de Jonge HR Rescue of the F508del CFTR trafficking defect in murine intestine by proteasome inhibitors. Pediatr Pulmonol Suppl 2005, 28:276.
98. Vij N, Fang S, Zeitlin PL Selective inhibition of endoplasmic reticulum-associated degradation rescues ΔF508-cystic fibrosis trans-membrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006, 281:17369-17378.
99. Trzcinska-Daneluti AM, Ly D, Huynh L, Jiang C, Fladd C, Rotin D High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteomics 2009, 8:780-790.
100. Norez C, Antigny F, Noel S, Vandebrouck C, Becq F A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009, 41:217-225.
101. Dechecchi MC, Nicolis E, Norez C, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros 2008, 7:555-565.
102. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009, 179:1022-1028.
103. Dormer RL, Dérand R, McNeilly CM, et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sei 2001, 114:4073-4081.
104. Stratford FL, Pereira MM, Becq F, McPherson MA, Dormer RL Benzo(c)quinolizinium drugs inhibit degradation of ΔF508-CFTR cytoplasmic domain. Biochem Biophys Res Commun 2003, 300:524-530.
105. Dechecchi MC, Nicolis E, Bezzerri V, et al. MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells. Am J Respir Cell Mol Biol 2007, 36:615-624.
106. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005, 60:55-59.
107. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008, 177:506-515.
108. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293:L712-L719.
109. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008, 73:478-489.
110. Yu GJ, Yoo CL, Yang B, et al. Potent s-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 2008, 51:6044-6054.
111. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacety-lase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010, 6:25-33.
112. Jiang C, Fang SL, Xiao YF, et al. Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF508 cells by de-oxyspergualin. Am J Physiol 1998, 275:C171-C178.
113. - channel functions. Am J Physiol Lung Cell Mol Physiol 2008, 295:L336-L347.
114. Rubenstein RC, Zeitlin PL A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998, 157:484-490.
115. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002, 6:119-126.
116. Arispe N, Ma J, Jacobson KA, Pollard HB Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-l,3-dipropylxanthine (CPX) and l,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1998, 273:5727-5734.
117. Al-Nakkash L, Hwang TC Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 1999, 437:553-561.
118. Weinreich F, Wood PG, Riordan JR, Nagel G Direct action of genistein on CFTR. Pflugers Arch 1997, 434:484-491.
119. - channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am J Physiol 1997, 273:C747-C753.
120. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999, 277:C833-C839.
121. Al-Nakkash L, Hu S, Li M, Hwang TC A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther 2001, 296:464-472.
122. Zegarra-Moran O, Romio L, Folli C, et al. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 2002, 137:504-512.
123. - channels expressed in murine cell line. J Physiol 2000, 524:317-330.
124. Derand R, Bulteau-Pignoux L, Becq F The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site. J Biol Chem 2002, 277:35999-36004.
125. Al-Nakkash L, Clarke LL, Rottinghaus GE, Chen YJ, Cooper K, Rubin LJ Dietary genistein stimulates anion secretion across female murine intestine. J Nutr 2006, 136:2785-2790.
126. Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. Am J Physiol Cell Physiol 2000, 279:C1838-C1846.
127. Becq F, Mettey Y, Gray MA, et al. Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 1999, 274:27415-27425.
128. Marivingt-Mounir C, Norez C, Dérand R, et al. Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J Med Chem 2004, 47:962-972.
129. Galietta LJ, Springsteel MF, Eda M, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001, 276:19723-19728.
130. Sammelson RE, Ma T, Galietta LJ, Verkman AS, Kurth MJ 3-(2-Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorg Med Chem Lett 2003, 13:2509-2512.
131. Caci E, Folli C, Zegarra-Moran O, et al. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 2003, 285:L180-L188.
132. Springsteel MF, Galietta LJ, Ma T, et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003, 11:4113-4120.
133. Ma T, Vetrivel L, Yang H, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002, 277:37235-37241.
134. - current by phloxine B. Br J Pharmacol 2000, 131:433-440.
135. Cai Z, Sheppard DN Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J Biol Chem 2002, 277:19546-19553.
136. Melin P, Norez C, Callebaut I, Becq F The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B. J Membr Biol 2005, 208:203-212.
137. - channel. J Biol Chem 2006, 281:1970-1977.
138. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J Biol Chem 2003, 278:35079-35085.
139. - channel activity. J Biol Chem 2005, 280:5221-5226.
140. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005, 67:1797-1807.
141. Caputo A, Hinzpeter A, Caci E, et al. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J Pharmacol Exp Ther 2009, 330:783-791.
142. Wang W, Li G, Clancy JP, Kirk KL Activating cystic fibrosis trans-membrane conductance regulator channels with pore blocker analogs. J Biol Chem 2005, 280:23622-23630.
143. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005, 68:1736-1746.
144. Pedemonte N, Boido D, Moran O, et al. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 2007, 72:197-207.
145. Murthy M, Pedemonte N, MacVinish L, Galietta L, Cuthbert A 4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and ΔF508 CFTR. Eur J Pharmacol 2005, 516:118-124.
146. Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, Bear CE A small-molecule modulator interacts directly with ΔPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 2009, 75:1430-1438.
147. Noel S, Faveau C, Norez C, Rogier C, Mettey Y, Becq F Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exp Ther 2006, 319:349-359.
148. Suen YF, Robins L, Yang B, Verkman AS, Nantz MH, Kurth MJ Sulfamoyl-4-oxoquinoline-3-carboxamides: novel potentiators of defective ΔF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 2006, 16:537-540.
149. Bertrand J, Boucherie B, Billet A, et al. Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-1 la. Eur Respir J 2010, 36:311-322.
150. McCarty NA, Standaert TA, Teresi M, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 2002, 33:90-98.